Orthofix Medical Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 5, 2025 and accepted by EDGAR at Aug 5, 2025, 11:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $203.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $396.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $63.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $135.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-04-01 to 2025-06-30 | $139.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2025-01-01 to 2025-06-30 | $261.2m | us-gaap:GrossProfit |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $15.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $35.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-04-01 to 2025-06-30 | $136.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-01-01 to 2025-06-30 | $269.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$16.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$64.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-04-01 to 2025-06-30 | −$142.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-30 | $819.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$14.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$67.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$0.36 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | −$1.71 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.36 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$1.71 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 39,501,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 39,317,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$6.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $13.8m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2025-06-30 | $65.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $395.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $837.2m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $148.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $378.8m | us-gaap:Liabilities |
| Long-term debt | At period end2025-06-30 | $157.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2025-06-30 | $458.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-25-102384. Last ingested by Listed: Oct 24, 2026, 14:59 ET. Listed shows no prices and gives no investment advice.